Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 250 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR “Solid Stress” Keeps Immune System from Killing Off Cancer Cells in... July 21, 2021 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... June 17, 2024 FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... March 20, 2025 Load more HOT NEWS ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... How My Cancer Diagnosis Has Fueled My Work in Improving Access...
